Curcumin analog GO-Y030 inhibits tumor metastasis and glycolysis

Abstract Tumor metastasis is one of the worst prognostic features of cancer. Although metastasis is a major cause of cancer-related deaths, an effective treatment has not yet been established. Here, we explore the antitumor effects of GO-Y030, a curcumin analog, via various mechanisms using a mouse...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biochemistry (Tokyo) 2023-11, Vol.174 (6), p.511-518
Main Authors: MaruYama, Takashi, Miyazaki, Hirofumi, Komori, Taishi, Osana, Shion, Shibata, Hiroyuki, Owada, Yuji, Kobayashi, Shuhei
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Curcumin - pharmacology
Endothelial Cells
Humans
Matrix Metalloproteinase 2
Neoplasm Metastasis
Neoplasms
Regular Paper
Transforming Growth Factor beta
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Tumor metastasis is one of the worst prognostic features of cancer. Although metastasis is a major cause of cancer-related deaths, an effective treatment has not yet been established. Here, we explore the antitumor effects of GO-Y030, a curcumin analog, via various mechanisms using a mouse model. GO-Y030 treatment of B16-F10 melanoma cells inhibited TGF-β expression and glycolysis. The invasion assay results showed almost complete invasion inhibition following GO-Y030 treatment. Mouse experiments demonstrated that GO-Y030 administration inhibited lung tumor metastasis without affecting vascular endothelial cells. Consistent with this result, GO-Y030 treatment led to the downregulation of MMP2 and VEGFα, inhibiting tumor invasion and metastasis. The silencing of eIF4B, a downstream molecule of S6, attenuated MMP2 expression. Our study demonstrates the novel efficacy of GO-Y030 in inhibiting tumor metastasis by regulating metastasis-associated gene expression via inhibiting dual access, glycolytic and TGF-β pathways. Graphical Abstract Graphical Abstract
ISSN:0021-924X
1756-2651
1756-2651
DOI:10.1093/jb/mvad066